Oral CAB

DRUG4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare

Conditions

HIV Infections

Phase 1

A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men

CompletedNCT03422172

ViiV HealthcareHIV Infections

Start: 2018-04-10End: 2020-04-20Updated: 2021-05-13

A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1

Not yet recruitingNCT07275606

ViiV HealthcareHIV Infections

Start: 2026-03-17End: 2029-10-10Target: 66Updated: 2025-12-10

Phase 3

Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

Active, not recruitingNCT03164564

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2017-11-07End: 2026-10-17Updated: 2025-10-09

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

Active, not recruitingNCT03635788

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2019-03-28End: 2026-08-30Updated: 2025-09-02

Related Papers

Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges.

2026-02-18

Advances in HIV Treatment and Vaccine Development: Emerging Therapies and Breakthrough Strategies for Long-Term Control.

2025-07-041 citations

Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial.

2025-03-124 citations

Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis

UNC Libraries2025-01-25

Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084

Antimicrobial Agents and Chemotherapy2024-09-272 citations

Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP

Antimicrobial Agents and Chemotherapy2024-05-067 citations

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.

2022-04-01401 citations

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.

2022-02-079 citations

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

AIDS2021-07-1392 citations

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).

2021-05-3156 citations

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

JAIDS Journal of Acquired Immune Deficiency Syndromes2020-08-21135 citations

Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.

2019-08-0871 citations

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

PLoS Medicine2018-11-08163 citations